Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

PeriGiene

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-198-08 D-0172-2026
Class II · Moderate risk

McKesson Skin Protectant

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 68599-6202-1 D-0171-2026
Class II · Moderate risk

Lantiseptic

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-304-05 D-0170-2026
Class II · Moderate risk

Lantiseptic

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-504-05 D-0169-2026
Class II · Moderate risk

KleenFoam Antimicrobial Foam Soap

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-093-34 D-0168-2026
Class II · Moderate risk

Hand-E-Foam

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-102-08 D-0167-2026
Class II · Moderate risk

GelRite Instant Hand Sanitizer

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-106-04 D-0166-2026
Class II · Moderate risk

DermaSarra

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-189-08 D-0165-2026
Class II · Moderate risk

DermaMed Ointment

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-214-04 D-0164-2026
Class II · Moderate risk

DermaKleen

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-092-08 D-0163-2026
Class II · Moderate risk

DermaFungal

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-234-05 D-0162-2026
Class II · Moderate risk

DermaCerin

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-174-04 D-0161-2026
Class II · Moderate risk

4-N-1 Skin Protectant

CGMP Deviation; manufactured at the same facility where other products and lots were found to be contaminated.

Ongoing cGMP deviation DermaRite Industries, LLC NDC 61924-208-04 D-0160-2026
Class II · Moderate risk

Ultra Violette

Subpotent/Super-potent Product: Testing of the SPF 50 sunscreen revealed inconsistency in SPF results ranging from SPF 4, 10, 21, 26, 33, 60, 61, and 64.

Ongoing Wrong potency / content Grace & Fire Pty LTD NDC 84803-106-01 D-0640-2025
Class II · Moderate risk

Sulfamethoxazole and Trimethoprim Tablets

Presence of a Foreign Substance: A specific lot of auxiliary polyester coil, used in product packaging by manufacturer (Amneal Pharmaceuticals LLC) was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Ongoing Particulate / foreign matter Northwind Pharmaceuticals LLC NDC 51655-307-87 D-0654-2025
Class II · Moderate risk

Carvedilol Tablets USP

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

Ongoing Nitrosamine impurity The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories NDC 0904-7307-61 D-0594-2025
Class II · Moderate risk

Dextroamphetamine Saccharate

Presence of Foreign Tablet/Capsule: Two (2) bottles labeled as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 10mg, 100ct, contained one (1) tablet of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, 5 mg.

Completed Particulate / foreign matter Lannett Company Inc. NDC 0527-0762-37 D-0642-2025
Class II · Moderate risk

chlorproMAZINE Hydrochloride Tablets

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Ongoing Particulate / foreign matter Amneal Pharmaceuticals, LLC NDC 69238-1062-1 D-0619-2025
Class II · Moderate risk

chlorproMAZINE Hydrochloride Tablets

Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging was detected with presence of a micro-organism. No micro-organism was detected on any tablets.

Ongoing Particulate / foreign matter Amneal Pharmaceuticals, LLC NDC 69238-1060-1 D-0618-2025

Recalls by year